HepSupport

❓ Myth: If you feel healthy, you definitely don't have Hepatitis C.

Let's clear up few a common misunderstandings.

Many people assume that feeling healthy means there couldn't be an underlying health condition to think about. However, Hepatitis C can sometimes remain unnoticed for years because symptoms may not appear straight away.

That's why testing is so important.🩺

Feeling well is a positive thing, but it doesn't always tell the full story. Testing isn't about creating worry—it's about providing reassurance and helping people access treatment if needed. Modern treatments are highly effective, and early diagnosis can help protect long-term liver health. 💚

By understanding the facts, we can reduce stigma and encourage more open conversations. Getting tested is simply a positive step towards looking after yourself and your future health. ✨

Fame meets political frustration.

This statement reflects a growing frustration with modern governance and education systems. By comparing the pay of politicians and teachers, it raises questions about incentives, accountability, and long term thinking

Even the WHO is celebrating the World Hepatitis Day.

tomorrow 28th july is WorldHepatitis Day.Take care of your liver.Awareness,councellingand testing as always ,hotline ...57015828

Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver

The principle pathological drivers of metabolic dysfunction-associated steatohepatitis (MASH) are obesity and associated insulin resistance, rendering them key therapeutic targets. As glucagon-like peptide 1 receptor agonists (GLP-1RAs) have been licensed for the treatment of diabetes and obesity, they were one of the first drug types to be evaluated in patients with MASH, and successful phase IIa and IIb studies have resulted in progression to phase III clinical trials. Alongside GLP-1RAs, newer combinations with glucagon agonists and/or glucose-dependent insulinotropic peptide (GIP) agonists have been explored in related patient groups, with evidence of improvements in weight, insulin resistance and non-invasive liver parameters. Whether GLP-1RAs have direct, independent effects on MASH or whether they impact on pathophysiology through improvements in weight, insulin resistance and glycaemic control remains a matter of debate. Combinations are being explored, although the potential improvement in efficacy will need to be weighed against the cumulative side-effect burden, potential drug-drug interactions and costs. There is also uncertainty regarding the optimal ratio of glucagon and GIP agonism to GLP-1 agonism in combination agents, and as to whether GIP agonism or antagonism is the optimal approach. Finally, there are also multiple hypothetical permutations combining gut hormone agonists with other emerging assets in the field. Given that the likely dominant mode of action of gut hormone agonists is upstream on weight, initial combinations might focus on agents which have been shown to have a more direct effect on fibrosis, which would include FGF21 and pan-PPAR agonists.

By Philip Newsome and Phil Ambery

Full review here: https://bit.ly/3EoHPxD

Part of our Thematic Miniseries on Promising Pharmacological Targets:
https://bit.ly/3R79MzR


EASL - The Home of Hepatology